Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTY-103
- Development stage
- Discontinued
- Lead developer
- Century Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Parenteral
01
Overview
CNTY-103 is an allogeneic, induced pluripotent stem cell-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy targeting CD133 and epidermal growth factor receptor (EGFR). It is developed as an immunotherapy and antineoplastic agent with mechanisms involving immunologic cytotoxicity and natural killer cell replacement. CNTY-103 was being investigated primarily for glioblastoma. This therapy was being developed by Century Therapeutics as a first-in-class iPSC-derived CAR-iNK product for solid tumors but has since been discontinued in the preclinical stage for glioblastoma[1][2][3][7].
- Other names
- CNTY-103CNTY103CNTY 103
02
Targets
CD133 (CD133 antigen)
Beyond the preview
Go deeper on CNTY-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTY-103.